MA4-Fc(N297A)-CD16AM19 demonstrated superior cytotoxicity against GPC3+ HCC cells compared to traditional monoclonal antibodies (hYP7(K)-LC21(H)), consistent with Kontermann’s “dual-signal activation threshold” model, where optimal spatial geometry reduces antigen density requirements for NK activation (37). This evidence concerns the gene GPC3 and hepatocellular carcinoma.